CSIMarket Company Name, Ticker, Industry, else..
 
Mural Oncology Plc  (NASDAQ: MURA)
 
Price: $2.0400 $0.00 0.000%
Day's High: $2.04 Week Perf: 0.49 %
Day's Low: $ 2.03 30 Day Perf: -1.92 %
Volume (M): 127,700 52 Wk High: $ 2.12
Volume (M$): $ 261 52 Wk Avg: $2.08
Open: $2.03 52 Wk Low: $2.02



 Market Capitalization (Millions $) 35
 Shares Outstanding (Millions) 17
 Employees 33
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -119
 Cash Flow (TTM) (Millions $) -52
 Capital Exp. (TTM) (Millions $) 0

Business Description


Mural Oncology Plc is a pharmaceutical company specializing in the development of targeted cancer therapies. The company focuses on creating innovative treatments that address unmet medical needs in various types of cancer. Mural Oncology Plc utilizes advanced technologies and research methods to identify and develop potential drug candidates with high efficacy and minimal side effects. The company's mission is to improve the lives of cancer patients by providing them with effective and personalized treatment options. Mural Oncology Plc is committed to advancing the field of oncology and making significant contributions to cancer research.


   Company Address: 10 Earlsfort Terrace Dublin 2 0
   Company Phone Number: 1-905-8020   Stock Exchange / Ticker: NASDAQ MURA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -6.83%    
MRK   -5.04%    
PFE   -4.46%    
SUPN   -4.5%    
TGTX   -3.99%    
ZLAB   -10.52%    
• View Complete Report
   



Management Announcement

Mural Oncology: Balancing Innovation and Financial Strain as Clinical Trials Approach,

Published Thu, Jan 9 2025 9:00 PM UTC

Mural Oncology: A Gamble in the High-Stakes Game of Immuno-OncologyIn the ever-evolving landscape of cancer treatment, Mural Oncology Plc stands at a precipice of promise and peril. The clinical-stage biotech firm, wading through significant financial turbulence, has staked its future on innovative therapies that could redefine patient outcomes in oncology. As the company pr...
Management Announcement

Mural Oncology Pioneers Innovative Therapies and Employee Incentives Amidst Tumultuous Market Conditions

Published Tue, Dec 3 2024 9:15 PM UTC

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)In a strategic move reflecting its commitment to both innovation and talent acquisition, Mural Oncology plc (Nasdaq: MURA), a clinical-stage company specializing in immuno-oncology, recently reported significant employment initiatives. On December 2, 2024, the company announced the granting of non-s...
Clinical Study

Evaluating the Clinical Promise of Nemvaleukin Amid Economic Challenges Insights from Mural Oncologys ARTISTRY-1 Tri...

Published Wed, Nov 20 2024 9:15 PM UTC

In a significant contribution to the field of oncology, Mural Oncology recently announced the publication of remarkable findings from its ARTISTRY-1 clinical trial, which investigates the therapeutic potential of its lead engineered fusion protein, Nemvaleukin. This trial, now documented in the Journal for ImmunoTherapy of Cancer, showcased promising clinical antitumor activ...
Clinical Study

Mural Oncology Strategic Pipeline Progress Amidst Market Underperformance

Published Wed, Nov 13 2024 12:00 PM UTC

Mural Oncology Plc recently announced its third quarter 2024 financial results alongside an update on its pipeline progress, attracting the attention of investors and industry analysts. While the company s shares have underperformed compared to the broader market over the past year, attention is notably focused on Mural Oncology s promising late-stage trials involving nemval...
Clinical Study

Enhancing Immunotherapy Mural Oncology’s Innovative Approaches in Tumor-Specific Pharmacodynamic Activity

Published Thu, Nov 7 2024 9:15 PM UTC

Immunotherapy has emerged as a promising cornerstone in the fight against cancer, showcasing substantial advances in patient outcomes. At the recent 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), Mural Oncology presented an array of compelling clinical and preclinical data from its research pipeline. Notably, the discussion centered around nemvaleukin...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.64
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.59
Working Capital Ratio 5.9
Leverage Ratio (MRQ) 0.19
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -6.94 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 3.4 $
Book Value 3.19 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -3,609,061
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -


  Mural Oncology Plc Outlook

On August 13 2024 the Mural Oncology Plc provided following guidance

nnMural Oncology Plc. Releases Financial Results for Q2 2024 and Shares Insights on Pipeline Developmentnn

Mural Oncology Plc. has disclosed its financial outcomes for the second quarter of 2024, along with an update regarding its pipeline advancements. The company has reaffirmed its previous financial guidance, emphasizing its anticipated cash runway extending through the fourth quarter of 2025.

The organization remains strategically positioned to leverage the promising role of cytokines in both the near and long term, highlighting potential value creation milestones on the horizon. The company's focus on harnessing cytokine therapies could pave the way for significant advancements in its ...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.